Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.
As part of the bio/pharmaceutical industry’s global response efforts for COVID-19, companies are also racing to develop therapies to treat COVID-19 in parallel with vaccine development efforts. As of Sept. 25, 2020, more than 590 drug development programs are in planning stages, and FDA has reviewed more than 310 trials, as of the end of August 2020, of potential COVID-19 therapies. The agency also published industry guidance in September 2020 around assessing symptoms in individuals undergoing clinical trials for COVID-19 therapies.
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 3–8
When referring to this article, please cite it as F. Mirasol, “Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies," BioPharm International Regulatory Sourcebook eBook (October 2020).
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.